Artemisinin-Derived Dimers Have Greatly Improved Anti-Cytomegalovirus Activity Compared to Artemisinin Monomers

Ravit Arav-Boger, Ran He, Chuang-Jiun Chiou et al. · 2010

Read Artemisinin-Derived Dimers Have Greatly Improved Anti-Cytomegalovirus Activity Compared to Artemisinin Monomers by Ravit Arav-Boger, Ran He, Chuang-Jiun Chiou et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0010370.txt.

Description

Ravit Arav-Boger and colleagues compared malaria-drug relatives against cytomegalovirus in PLOS ONE in 2010. The virus, called CMV, can cause grave illness in people with weak immunity. A plant-derived drug, artesunate, had been reported to slow CMV growth. The team tested several single-unit forms of the drug family. They also built and tested new double-unit forms, called dimers.

In lab tests, the dimers fought the virus far better than the single forms. Doubling the molecule greatly raised its strength. That kind of jump can revive a drug family once set aside. More testing would be needed for safety and dosing. For now, the study marks dimers as the form worth pursuing against CMV.

Catalog record

CREATORRavit Arav-Boger, Ran He, Chuang-Jiun Chiou et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010370

Browse the full library · About the Tower of Babel